# Kensuke Usuki

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kensuke-usuki/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,521 |
| Field | Acute Myeloid Leukemia Research |
| h-index | 39 |
| i10-index | 124 |
| Last Known Institution | Teikyo University |
| OpenAlex ID | https://openalex.org/A5021004681 |
| ORCID iD | 0000-0002-1216-4470 |
| Works | 373 |

## Researcher papers

Showing 12 of 13.

- [Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor](https://scholariq.org/papers/identification-of-angiogenic-activity-and-the-cloning-and-expression-of-platelet/)
- [Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria](https://scholariq.org/papers/pegcetacoplan-versus-eculizumab-in-paroxysmal-nocturnal-hemoglobinuria/)
- [Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial](https://scholariq.org/papers/discontinuation-of-dasatinib-in-patients-with-chronic-myeloid-leukaemia-who-have/)
- [A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders](https://scholariq.org/papers/a-sensitive-sandwich-elisa-for-measuring-thrombopoietin-in-human-serum-serum/)
- [Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity](https://scholariq.org/papers/platelet-derived-endothelial-cell-growth-factor-has-thymidine-phosphorylase/)
- [Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia](https://scholariq.org/papers/discontinuation-of-imatinib-in-japanese-patients-with-chronic-myeloid-leukemia/)
- [The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria](https://scholariq.org/papers/the-complement-c5-inhibitor-crovalimab-in-paroxysmal-nocturnal-hemoglobinuria/)
- [Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia](https://scholariq.org/papers/prognostic-impact-of-low-allelic-ratio-flt3-itd-and-npm1-mutation-in-acute/)
- [Prognostic impact of <i>CEBPA</i> bZIP domain mutation in acute myeloid leukemia](https://scholariq.org/papers/prognostic-impact-of-i-cebpa-i-bzip-domain-mutation-in-acute-myeloid-leukemia/)
- [Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment](https://scholariq.org/papers/final-3-year-results-of-the-dasatinib-discontinuation-trial-in-patients-with/)
- [Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria](https://scholariq.org/papers/eculizumab-dosing-intervals-longer-than-17-days-may-be-associated-with-greater/)
- [Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients](https://scholariq.org/papers/results-from-multinational-phase-3-studies-of-ravulizumab-alxn1210-versus/)

## Researcher topics

- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Myeloproliferative Neoplasms: Diagnosis and Treatment](https://scholariq.org/topics/myeloproliferative-neoplasms-diagnosis-and-treatment/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)

## Researcher university

- [Teikyo University](https://scholariq.org/institutions/teikyo-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.